nodes	percent_of_prediction	percent_of_DWPC	metapath
Tapentadol—Thinking abnormal—Carmustine—melanoma	0.00508	0.0097	CcSEcCtD
Tapentadol—Drug interaction—Carmustine—melanoma	0.00502	0.00957	CcSEcCtD
Tapentadol—Weight decreased—Vemurafenib—melanoma	0.005	0.00953	CcSEcCtD
Tapentadol—Infestation NOS—Vemurafenib—melanoma	0.00492	0.00939	CcSEcCtD
Tapentadol—Infestation—Vemurafenib—melanoma	0.00492	0.00939	CcSEcCtD
Tapentadol—Coordination abnormal—Carmustine—melanoma	0.00474	0.00904	CcSEcCtD
Tapentadol—Coordination abnormal—Temozolomide—melanoma	0.00458	0.00874	CcSEcCtD
Tapentadol—Depressed level of consciousness—Carmustine—melanoma	0.00449	0.00857	CcSEcCtD
Tapentadol—Depressed level of consciousness—Temozolomide—melanoma	0.00434	0.00828	CcSEcCtD
Tapentadol—Connective tissue disorder—Vemurafenib—melanoma	0.00434	0.00828	CcSEcCtD
Tapentadol—Disorientation—Bleomycin—melanoma	0.00433	0.00825	CcSEcCtD
Tapentadol—Eye disorder—Vemurafenib—melanoma	0.00413	0.00788	CcSEcCtD
Tapentadol—Cardiac disorder—Vemurafenib—melanoma	0.0041	0.00782	CcSEcCtD
Tapentadol—Mental disability—Carmustine—melanoma	0.00404	0.0077	CcSEcCtD
Tapentadol—Angiopathy—Vemurafenib—melanoma	0.00401	0.00765	CcSEcCtD
Tapentadol—Mediastinal disorder—Vemurafenib—melanoma	0.00398	0.0076	CcSEcCtD
Tapentadol—Chills—Vemurafenib—melanoma	0.00397	0.00756	CcSEcCtD
Tapentadol—Mental disability—Temozolomide—melanoma	0.0039	0.00744	CcSEcCtD
Tapentadol—Malnutrition—Vemurafenib—melanoma	0.00385	0.00734	CcSEcCtD
Tapentadol—Lethargy—Dactinomycin—melanoma	0.00368	0.00703	CcSEcCtD
Tapentadol—Hot flush—Temozolomide—melanoma	0.00349	0.00666	CcSEcCtD
Tapentadol—Menopausal symptoms—Temozolomide—melanoma	0.00346	0.0066	CcSEcCtD
Tapentadol—Cough—Vemurafenib—melanoma	0.00336	0.0064	CcSEcCtD
Tapentadol—Arthralgia—Vemurafenib—melanoma	0.00328	0.00625	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00325	0.0062	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00325	0.0062	CcSEcCtD
Tapentadol—Drug interaction—Docetaxel—melanoma	0.00322	0.00615	CcSEcCtD
Tapentadol—Ataxia—Carmustine—melanoma	0.00318	0.00606	CcSEcCtD
Tapentadol—Anaphylactic shock—Vemurafenib—melanoma	0.00314	0.00599	CcSEcCtD
Tapentadol—Infection—Vemurafenib—melanoma	0.00312	0.00595	CcSEcCtD
Tapentadol—Nervous system disorder—Vemurafenib—melanoma	0.00308	0.00587	CcSEcCtD
Tapentadol—Ataxia—Temozolomide—melanoma	0.00307	0.00586	CcSEcCtD
Tapentadol—Skin disorder—Vemurafenib—melanoma	0.00305	0.00582	CcSEcCtD
Tapentadol—Weight decreased—Bleomycin—melanoma	0.00303	0.00577	CcSEcCtD
Tapentadol—Breast disorder—Temozolomide—melanoma	0.00295	0.00563	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Temozolomide—melanoma	0.00294	0.00561	CcSEcCtD
Tapentadol—Hypotension—Vemurafenib—melanoma	0.00293	0.0056	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Temozolomide—melanoma	0.00288	0.00549	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00286	0.00546	CcSEcCtD
Tapentadol—Decreased appetite—Vemurafenib—melanoma	0.00273	0.00521	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00271	0.00517	CcSEcCtD
Tapentadol—Fatigue—Vemurafenib—melanoma	0.00271	0.00516	CcSEcCtD
Tapentadol—Constipation—Vemurafenib—melanoma	0.00269	0.00512	CcSEcCtD
Tapentadol—Hypoaesthesia—Bleomycin—melanoma	0.00266	0.00508	CcSEcCtD
Tapentadol—Upper respiratory tract infection—Temozolomide—melanoma	0.00262	0.005	CcSEcCtD
Tapentadol—Pollakiuria—Temozolomide—melanoma	0.00261	0.00497	CcSEcCtD
Tapentadol—Erectile dysfunction—Temozolomide—melanoma	0.0026	0.00496	CcSEcCtD
Tapentadol—Depression—Carmustine—melanoma	0.0026	0.00495	CcSEcCtD
Tapentadol—Weight decreased—Temozolomide—melanoma	0.00255	0.00487	CcSEcCtD
Tapentadol—Urinary tract infection—Carmustine—melanoma	0.00253	0.00483	CcSEcCtD
Tapentadol—Infestation NOS—Temozolomide—melanoma	0.00252	0.0048	CcSEcCtD
Tapentadol—Infestation—Temozolomide—melanoma	0.00252	0.0048	CcSEcCtD
Tapentadol—Depression—Temozolomide—melanoma	0.00251	0.00478	CcSEcCtD
Tapentadol—Urinary tract infection—Temozolomide—melanoma	0.00245	0.00466	CcSEcCtD
Tapentadol—Chills—Bleomycin—melanoma	0.0024	0.00458	CcSEcCtD
Tapentadol—Hallucination—Carmustine—melanoma	0.00233	0.00444	CcSEcCtD
Tapentadol—Hypoaesthesia—Carmustine—melanoma	0.00233	0.00444	CcSEcCtD
Tapentadol—Hot flush—Docetaxel—melanoma	0.00232	0.00443	CcSEcCtD
Tapentadol—Hypersensitivity—Vemurafenib—melanoma	0.00231	0.00441	CcSEcCtD
Tapentadol—Menopausal symptoms—Docetaxel—melanoma	0.0023	0.00439	CcSEcCtD
Tapentadol—Connective tissue disorder—Carmustine—melanoma	0.0023	0.00438	CcSEcCtD
Tapentadol—Visual disturbance—Docetaxel—melanoma	0.00229	0.00437	CcSEcCtD
Tapentadol—Asthenia—Vemurafenib—melanoma	0.00225	0.0043	CcSEcCtD
Tapentadol—Visual impairment—Carmustine—melanoma	0.00225	0.0043	CcSEcCtD
Tapentadol—Hypoaesthesia—Temozolomide—melanoma	0.00225	0.00429	CcSEcCtD
Tapentadol—Hallucination—Temozolomide—melanoma	0.00225	0.00429	CcSEcCtD
Tapentadol—Chills—Dactinomycin—melanoma	0.00224	0.00427	CcSEcCtD
Tapentadol—Urinary tract disorder—Temozolomide—melanoma	0.00223	0.00425	CcSEcCtD
Tapentadol—Pruritus—Vemurafenib—melanoma	0.00222	0.00424	CcSEcCtD
Tapentadol—Connective tissue disorder—Temozolomide—melanoma	0.00222	0.00423	CcSEcCtD
Tapentadol—Lethargy—Docetaxel—melanoma	0.00222	0.00423	CcSEcCtD
Tapentadol—Urethral disorder—Temozolomide—melanoma	0.00221	0.00422	CcSEcCtD
Tapentadol—Eye disorder—Carmustine—melanoma	0.00218	0.00417	CcSEcCtD
Tapentadol—Visual impairment—Temozolomide—melanoma	0.00218	0.00415	CcSEcCtD
Tapentadol—Diarrhoea—Vemurafenib—melanoma	0.00215	0.0041	CcSEcCtD
Tapentadol—Eye disorder—Temozolomide—melanoma	0.00211	0.00403	CcSEcCtD
Tapentadol—Cardiac disorder—Temozolomide—melanoma	0.0021	0.004	CcSEcCtD
Tapentadol—Dizziness—Vemurafenib—melanoma	0.00208	0.00396	CcSEcCtD
Tapentadol—Angiopathy—Temozolomide—melanoma	0.00205	0.00391	CcSEcCtD
Tapentadol—Mental disorder—Carmustine—melanoma	0.00205	0.00391	CcSEcCtD
Tapentadol—Ataxia—Docetaxel—melanoma	0.00204	0.00389	CcSEcCtD
Tapentadol—Immune system disorder—Temozolomide—melanoma	0.00204	0.00389	CcSEcCtD
Tapentadol—Mediastinal disorder—Temozolomide—melanoma	0.00204	0.00388	CcSEcCtD
Tapentadol—Malnutrition—Carmustine—melanoma	0.00203	0.00388	CcSEcCtD
Tapentadol—Cough—Bleomycin—melanoma	0.00203	0.00388	CcSEcCtD
Tapentadol—Chills—Temozolomide—melanoma	0.00203	0.00387	CcSEcCtD
Tapentadol—Vomiting—Vemurafenib—melanoma	0.002	0.00381	CcSEcCtD
Tapentadol—Rash—Vemurafenib—melanoma	0.00198	0.00378	CcSEcCtD
Tapentadol—Mental disorder—Temozolomide—melanoma	0.00198	0.00377	CcSEcCtD
Tapentadol—Dermatitis—Vemurafenib—melanoma	0.00198	0.00377	CcSEcCtD
Tapentadol—Headache—Vemurafenib—melanoma	0.00197	0.00375	CcSEcCtD
Tapentadol—Malnutrition—Temozolomide—melanoma	0.00197	0.00375	CcSEcCtD
Tapentadol—Breast disorder—Docetaxel—melanoma	0.00196	0.00374	CcSEcCtD
Tapentadol—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00196	0.00373	CcSEcCtD
Tapentadol—Nasopharyngitis—Docetaxel—melanoma	0.00194	0.0037	CcSEcCtD
Tapentadol—Confusional state—Bleomycin—melanoma	0.00192	0.00366	CcSEcCtD
Tapentadol—Vision blurred—Carmustine—melanoma	0.00192	0.00366	CcSEcCtD
Tapentadol—Alanine aminotransferase increased—Docetaxel—melanoma	0.00192	0.00365	CcSEcCtD
Tapentadol—Tremor—Carmustine—melanoma	0.00191	0.00364	CcSEcCtD
Tapentadol—Oedema—Bleomycin—melanoma	0.0019	0.00363	CcSEcCtD
Tapentadol—Anaphylactic shock—Bleomycin—melanoma	0.0019	0.00363	CcSEcCtD
Tapentadol—Infection—Bleomycin—melanoma	0.00189	0.0036	CcSEcCtD
Tapentadol—Agitation—Carmustine—melanoma	0.00187	0.00357	CcSEcCtD
Tapentadol—Nausea—Vemurafenib—melanoma	0.00187	0.00356	CcSEcCtD
Tapentadol—Vision blurred—Temozolomide—melanoma	0.00185	0.00353	CcSEcCtD
Tapentadol—Tremor—Temozolomide—melanoma	0.00184	0.00351	CcSEcCtD
Tapentadol—Agitation—Temozolomide—melanoma	0.00181	0.00345	CcSEcCtD
Tapentadol—Angioedema—Temozolomide—melanoma	0.0018	0.00343	CcSEcCtD
Tapentadol—Hypotension—Bleomycin—melanoma	0.00178	0.00339	CcSEcCtD
Tapentadol—Oedema—Dactinomycin—melanoma	0.00177	0.00338	CcSEcCtD
Tapentadol—Vertigo—Temozolomide—melanoma	0.00177	0.00337	CcSEcCtD
Tapentadol—Convulsion—Carmustine—melanoma	0.00176	0.00336	CcSEcCtD
Tapentadol—Infection—Dactinomycin—melanoma	0.00176	0.00336	CcSEcCtD
Tapentadol—Palpitations—Temozolomide—melanoma	0.00174	0.00331	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Bleomycin—melanoma	0.00173	0.00331	CcSEcCtD
Tapentadol—Anxiety—Carmustine—melanoma	0.00173	0.00329	CcSEcCtD
Tapentadol—Cough—Temozolomide—melanoma	0.00172	0.00327	CcSEcCtD
Tapentadol—Paraesthesia—Bleomycin—melanoma	0.00171	0.00326	CcSEcCtD
Tapentadol—Convulsion—Temozolomide—melanoma	0.0017	0.00325	CcSEcCtD
Tapentadol—Weight decreased—Docetaxel—melanoma	0.0017	0.00324	CcSEcCtD
Tapentadol—Dyspnoea—Bleomycin—melanoma	0.0017	0.00323	CcSEcCtD
Tapentadol—Confusional state—Carmustine—melanoma	0.00167	0.00319	CcSEcCtD
Tapentadol—Arthralgia—Temozolomide—melanoma	0.00167	0.00319	CcSEcCtD
Tapentadol—Infestation—Docetaxel—melanoma	0.00167	0.00319	CcSEcCtD
Tapentadol—Infestation NOS—Docetaxel—melanoma	0.00167	0.00319	CcSEcCtD
Tapentadol—Anxiety—Temozolomide—melanoma	0.00167	0.00318	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00166	0.00317	CcSEcCtD
Tapentadol—Oedema—Carmustine—melanoma	0.00166	0.00317	CcSEcCtD
Tapentadol—Decreased appetite—Bleomycin—melanoma	0.00165	0.00315	CcSEcCtD
Tapentadol—Infection—Carmustine—melanoma	0.00165	0.00315	CcSEcCtD
Tapentadol—Dry mouth—Temozolomide—melanoma	0.00164	0.00312	CcSEcCtD
Tapentadol—Tachycardia—Carmustine—melanoma	0.00162	0.00309	CcSEcCtD
Tapentadol—Confusional state—Temozolomide—melanoma	0.00162	0.00309	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00162	0.00308	CcSEcCtD
Tapentadol—Oedema—Temozolomide—melanoma	0.0016	0.00306	CcSEcCtD
Tapentadol—Anaphylactic shock—Temozolomide—melanoma	0.0016	0.00306	CcSEcCtD
Tapentadol—Infection—Temozolomide—melanoma	0.00159	0.00304	CcSEcCtD
Tapentadol—Nervous system disorder—Temozolomide—melanoma	0.00157	0.003	CcSEcCtD
Tapentadol—Feeling abnormal—Bleomycin—melanoma	0.00157	0.00299	CcSEcCtD
Tapentadol—Skin disorder—Temozolomide—melanoma	0.00156	0.00297	CcSEcCtD
Tapentadol—Hypotension—Carmustine—melanoma	0.00155	0.00296	CcSEcCtD
Tapentadol—Hyperhidrosis—Temozolomide—melanoma	0.00155	0.00296	CcSEcCtD
Tapentadol—Decreased appetite—Dactinomycin—melanoma	0.00154	0.00294	CcSEcCtD
Tapentadol—Fatigue—Dactinomycin—melanoma	0.00153	0.00292	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Carmustine—melanoma	0.00151	0.00289	CcSEcCtD
Tapentadol—Urticaria—Bleomycin—melanoma	0.00151	0.00288	CcSEcCtD
Tapentadol—Insomnia—Carmustine—melanoma	0.0015	0.00286	CcSEcCtD
Tapentadol—Hypoaesthesia—Docetaxel—melanoma	0.00149	0.00285	CcSEcCtD
Tapentadol—Paraesthesia—Carmustine—melanoma	0.00149	0.00284	CcSEcCtD
Tapentadol—Urinary tract disorder—Docetaxel—melanoma	0.00148	0.00283	CcSEcCtD
Tapentadol—Dyspnoea—Carmustine—melanoma	0.00148	0.00282	CcSEcCtD
Tapentadol—Somnolence—Carmustine—melanoma	0.00148	0.00282	CcSEcCtD
Tapentadol—Connective tissue disorder—Docetaxel—melanoma	0.00148	0.00282	CcSEcCtD
Tapentadol—Urethral disorder—Docetaxel—melanoma	0.00147	0.00281	CcSEcCtD
Tapentadol—Feeling abnormal—Dactinomycin—melanoma	0.00146	0.00279	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Temozolomide—melanoma	0.00146	0.00279	CcSEcCtD
Tapentadol—Insomnia—Temozolomide—melanoma	0.00145	0.00277	CcSEcCtD
Tapentadol—Visual impairment—Docetaxel—melanoma	0.00145	0.00276	CcSEcCtD
Tapentadol—Decreased appetite—Carmustine—melanoma	0.00144	0.00275	CcSEcCtD
Tapentadol—Paraesthesia—Temozolomide—melanoma	0.00144	0.00275	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Carmustine—melanoma	0.00143	0.00273	CcSEcCtD
Tapentadol—Dyspnoea—Temozolomide—melanoma	0.00143	0.00273	CcSEcCtD
Tapentadol—Somnolence—Temozolomide—melanoma	0.00143	0.00272	CcSEcCtD
Tapentadol—Constipation—Carmustine—melanoma	0.00142	0.00271	CcSEcCtD
Tapentadol—Dyspepsia—Temozolomide—melanoma	0.00141	0.00269	CcSEcCtD
Tapentadol—Eye disorder—Docetaxel—melanoma	0.0014	0.00268	CcSEcCtD
Tapentadol—Hypersensitivity—Bleomycin—melanoma	0.0014	0.00267	CcSEcCtD
Tapentadol—Decreased appetite—Temozolomide—melanoma	0.0014	0.00266	CcSEcCtD
Tapentadol—Cardiac disorder—Docetaxel—melanoma	0.00139	0.00266	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Temozolomide—melanoma	0.00139	0.00264	CcSEcCtD
Tapentadol—Fatigue—Temozolomide—melanoma	0.00138	0.00264	CcSEcCtD
Tapentadol—Constipation—Temozolomide—melanoma	0.00137	0.00262	CcSEcCtD
Tapentadol—Feeling abnormal—Carmustine—melanoma	0.00137	0.00261	CcSEcCtD
Tapentadol—Asthenia—Bleomycin—melanoma	0.00137	0.0026	CcSEcCtD
Tapentadol—Angiopathy—Docetaxel—melanoma	0.00136	0.0026	CcSEcCtD
Tapentadol—Immune system disorder—Docetaxel—melanoma	0.00136	0.00259	CcSEcCtD
Tapentadol—Mediastinal disorder—Docetaxel—melanoma	0.00135	0.00258	CcSEcCtD
Tapentadol—Chills—Docetaxel—melanoma	0.00135	0.00257	CcSEcCtD
Tapentadol—Pruritus—Bleomycin—melanoma	0.00135	0.00257	CcSEcCtD
Tapentadol—Feeling abnormal—Temozolomide—melanoma	0.00132	0.00252	CcSEcCtD
Tapentadol—Mental disorder—Docetaxel—melanoma	0.00132	0.00251	CcSEcCtD
Tapentadol—Malnutrition—Docetaxel—melanoma	0.00131	0.00249	CcSEcCtD
Tapentadol—Hypersensitivity—Dactinomycin—melanoma	0.00131	0.00249	CcSEcCtD
Tapentadol—Urticaria—Temozolomide—melanoma	0.00127	0.00243	CcSEcCtD
Tapentadol—Asthenia—Dactinomycin—melanoma	0.00127	0.00243	CcSEcCtD
Tapentadol—Hypersensitivity—Carmustine—melanoma	0.00122	0.00233	CcSEcCtD
Tapentadol—Diarrhoea—Dactinomycin—melanoma	0.00121	0.00232	CcSEcCtD
Tapentadol—Vomiting—Bleomycin—melanoma	0.00121	0.00231	CcSEcCtD
Tapentadol—Rash—Bleomycin—melanoma	0.0012	0.00229	CcSEcCtD
Tapentadol—Dermatitis—Bleomycin—melanoma	0.0012	0.00229	CcSEcCtD
Tapentadol—Asthenia—Carmustine—melanoma	0.00119	0.00227	CcSEcCtD
Tapentadol—Hypersensitivity—Temozolomide—melanoma	0.00118	0.00225	CcSEcCtD
Tapentadol—Syncope—Docetaxel—melanoma	0.00117	0.00224	CcSEcCtD
Tapentadol—Palpitations—Docetaxel—melanoma	0.00116	0.0022	CcSEcCtD
Tapentadol—Asthenia—Temozolomide—melanoma	0.00115	0.0022	CcSEcCtD
Tapentadol—Loss of consciousness—Docetaxel—melanoma	0.00115	0.00219	CcSEcCtD
Tapentadol—Cough—Docetaxel—melanoma	0.00114	0.00218	CcSEcCtD
Tapentadol—Diarrhoea—Carmustine—melanoma	0.00114	0.00217	CcSEcCtD
Tapentadol—Pruritus—Temozolomide—melanoma	0.00114	0.00217	CcSEcCtD
Tapentadol—Convulsion—Docetaxel—melanoma	0.00113	0.00216	CcSEcCtD
Tapentadol—Nausea—Bleomycin—melanoma	0.00113	0.00216	CcSEcCtD
Tapentadol—Vomiting—Dactinomycin—melanoma	0.00113	0.00215	CcSEcCtD
Tapentadol—Rash—Dactinomycin—melanoma	0.00112	0.00213	CcSEcCtD
Tapentadol—Arthralgia—Docetaxel—melanoma	0.00111	0.00212	CcSEcCtD
Tapentadol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00111	0.00211	CcSEcCtD
Tapentadol—Dizziness—Carmustine—melanoma	0.0011	0.00209	CcSEcCtD
Tapentadol—Diarrhoea—Temozolomide—melanoma	0.0011	0.00209	CcSEcCtD
Tapentadol—Dry mouth—Docetaxel—melanoma	0.00109	0.00208	CcSEcCtD
Tapentadol—Confusional state—Docetaxel—melanoma	0.00108	0.00205	CcSEcCtD
Tapentadol—Anaphylactic shock—Docetaxel—melanoma	0.00107	0.00204	CcSEcCtD
Tapentadol—Oedema—Docetaxel—melanoma	0.00107	0.00204	CcSEcCtD
Tapentadol—Dizziness—Temozolomide—melanoma	0.00106	0.00202	CcSEcCtD
Tapentadol—Infection—Docetaxel—melanoma	0.00106	0.00202	CcSEcCtD
Tapentadol—Vomiting—Carmustine—melanoma	0.00106	0.00201	CcSEcCtD
Tapentadol—Nausea—Dactinomycin—melanoma	0.00105	0.00201	CcSEcCtD
Tapentadol—Shock—Docetaxel—melanoma	0.00105	0.002	CcSEcCtD
Tapentadol—Rash—Carmustine—melanoma	0.00105	0.002	CcSEcCtD
Tapentadol—Nervous system disorder—Docetaxel—melanoma	0.00105	0.002	CcSEcCtD
Tapentadol—Dermatitis—Carmustine—melanoma	0.00105	0.002	CcSEcCtD
Tapentadol—Tachycardia—Docetaxel—melanoma	0.00104	0.00199	CcSEcCtD
Tapentadol—Headache—Carmustine—melanoma	0.00104	0.00198	CcSEcCtD
Tapentadol—Skin disorder—Docetaxel—melanoma	0.00104	0.00198	CcSEcCtD
Tapentadol—Vomiting—Temozolomide—melanoma	0.00102	0.00195	CcSEcCtD
Tapentadol—Rash—Temozolomide—melanoma	0.00101	0.00193	CcSEcCtD
Tapentadol—Dermatitis—Temozolomide—melanoma	0.00101	0.00193	CcSEcCtD
Tapentadol—Headache—Temozolomide—melanoma	0.00101	0.00192	CcSEcCtD
Tapentadol—Hypotension—Docetaxel—melanoma	0.000997	0.0019	CcSEcCtD
Tapentadol—Nausea—Carmustine—melanoma	0.000986	0.00188	CcSEcCtD
Tapentadol—Musculoskeletal discomfort—Docetaxel—melanoma	0.000972	0.00185	CcSEcCtD
Tapentadol—Insomnia—Docetaxel—melanoma	0.000965	0.00184	CcSEcCtD
Tapentadol—Paraesthesia—Docetaxel—melanoma	0.000958	0.00183	CcSEcCtD
Tapentadol—Nausea—Temozolomide—melanoma	0.000953	0.00182	CcSEcCtD
Tapentadol—Dyspnoea—Docetaxel—melanoma	0.000952	0.00181	CcSEcCtD
Tapentadol—Somnolence—Docetaxel—melanoma	0.000949	0.00181	CcSEcCtD
Tapentadol—Dyspepsia—Docetaxel—melanoma	0.00094	0.00179	CcSEcCtD
Tapentadol—Decreased appetite—Docetaxel—melanoma	0.000928	0.00177	CcSEcCtD
Tapentadol—Gastrointestinal disorder—Docetaxel—melanoma	0.000921	0.00176	CcSEcCtD
Tapentadol—Fatigue—Docetaxel—melanoma	0.00092	0.00175	CcSEcCtD
Tapentadol—Constipation—Docetaxel—melanoma	0.000913	0.00174	CcSEcCtD
Tapentadol—Feeling abnormal—Docetaxel—melanoma	0.00088	0.00168	CcSEcCtD
Tapentadol—Hypersensitivity—Docetaxel—melanoma	0.000786	0.0015	CcSEcCtD
Tapentadol—Asthenia—Docetaxel—melanoma	0.000766	0.00146	CcSEcCtD
Tapentadol—Pruritus—Docetaxel—melanoma	0.000755	0.00144	CcSEcCtD
Tapentadol—Diarrhoea—Docetaxel—melanoma	0.00073	0.00139	CcSEcCtD
Tapentadol—Dizziness—Docetaxel—melanoma	0.000706	0.00135	CcSEcCtD
Tapentadol—Vomiting—Docetaxel—melanoma	0.000679	0.00129	CcSEcCtD
Tapentadol—Rash—Docetaxel—melanoma	0.000673	0.00128	CcSEcCtD
Tapentadol—Dermatitis—Docetaxel—melanoma	0.000672	0.00128	CcSEcCtD
Tapentadol—Headache—Docetaxel—melanoma	0.000669	0.00128	CcSEcCtD
Tapentadol—Nausea—Docetaxel—melanoma	0.000634	0.00121	CcSEcCtD
Tapentadol—OPRK1—Signaling Pathways—HIF1A—melanoma	5.56e-05	0.000117	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGF—melanoma	5.52e-05	0.000116	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CSF2—melanoma	5.51e-05	0.000116	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGF1—melanoma	5.51e-05	0.000116	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CD—melanoma	5.48e-05	0.000115	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—IL2—melanoma	5.43e-05	0.000114	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—ALB—melanoma	5.41e-05	0.000114	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—E2F1—melanoma	5.39e-05	0.000113	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CB—melanoma	5.37e-05	0.000113	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK3—melanoma	5.35e-05	0.000112	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	5.34e-05	0.000112	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PDGFRA—melanoma	5.34e-05	0.000112	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KDR—melanoma	5.32e-05	0.000112	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.31e-05	0.000112	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ITGB3—melanoma	5.28e-05	0.000111	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PRKCA—melanoma	5.28e-05	0.000111	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—BRAF—melanoma	5.25e-05	0.00011	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—VCAN—melanoma	5.19e-05	0.000109	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—SPP1—melanoma	5.18e-05	0.000109	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAP2K2—melanoma	5.17e-05	0.000109	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—CXCL8—melanoma	5.16e-05	0.000108	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—melanoma	5.16e-05	0.000108	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—VCAN—melanoma	5.15e-05	0.000108	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FN1—melanoma	5.12e-05	0.000108	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IGF1—melanoma	5.11e-05	0.000108	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—MAPK1—melanoma	5.09e-05	0.000107	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—EGFR—melanoma	5.09e-05	0.000107	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CG—melanoma	5.06e-05	0.000106	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NOTCH1—melanoma	5.01e-05	0.000105	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAP2K1—melanoma	4.94e-05	0.000104	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL2—melanoma	4.93e-05	0.000104	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TERT—melanoma	4.91e-05	0.000103	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CD—melanoma	4.91e-05	0.000103	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CD80—melanoma	4.91e-05	0.000103	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—RAC1—melanoma	4.9e-05	0.000103	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CG—melanoma	4.9e-05	0.000103	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—APC—melanoma	4.9e-05	0.000103	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KIT—melanoma	4.9e-05	0.000103	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—NRAS—melanoma	4.9e-05	0.000103	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PPARG—melanoma	4.89e-05	0.000103	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	4.87e-05	0.000102	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—PIK3CA—melanoma	4.86e-05	0.000102	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGF—melanoma	4.84e-05	0.000102	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—KRAS—melanoma	4.81e-05	0.000101	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CB—melanoma	4.77e-05	0.0001	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP17A1—melanoma	4.76e-05	0.0001	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTGS2—melanoma	4.73e-05	9.95e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—melanoma	4.7e-05	9.89e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—FGF2—melanoma	4.7e-05	9.89e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HIF1A—melanoma	4.7e-05	9.88e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.7e-05	9.88e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK3—melanoma	4.69e-05	9.86e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	4.64e-05	9.75e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—BRAF—melanoma	4.6e-05	9.68e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GNA11—melanoma	4.5e-05	9.46e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KDR—melanoma	4.49e-05	9.45e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IGF1—melanoma	4.48e-05	9.43e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—MAPK1—melanoma	4.46e-05	9.38e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—EGFR—melanoma	4.46e-05	9.38e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CD—melanoma	4.45e-05	9.36e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—PIK3CA—melanoma	4.42e-05	9.29e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—FASN—melanoma	4.4e-05	9.25e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MDM2—melanoma	4.4e-05	9.25e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—ALB—melanoma	4.39e-05	9.24e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP17A1—melanoma	4.38e-05	9.21e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP17A1—melanoma	4.34e-05	9.13e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—ERBB2—melanoma	4.34e-05	9.12e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAP2K1—melanoma	4.33e-05	9.11e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—SLC5A5—melanoma	4.33e-05	9.1e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FN1—melanoma	4.33e-05	9.09e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CD—melanoma	4.31e-05	9.05e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	4.28e-05	9e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CB—melanoma	4.28e-05	9e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—PIK3CA—melanoma	4.26e-05	8.97e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NOTCH1—melanoma	4.23e-05	8.9e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—melanoma	4.23e-05	8.89e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—KRAS—melanoma	4.22e-05	8.86e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—GNAQ—melanoma	4.18e-05	8.79e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CD44—melanoma	4.18e-05	8.79e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CD80—melanoma	4.15e-05	8.72e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—APC—melanoma	4.14e-05	8.7e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CG—melanoma	4.14e-05	8.7e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KIT—melanoma	4.14e-05	8.7e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—NRAS—melanoma	4.14e-05	8.7e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GNA11—melanoma	4.14e-05	8.7e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PTEN—melanoma	4.12e-05	8.67e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—FGF2—melanoma	4.12e-05	8.67e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CXCL8—melanoma	4.11e-05	8.65e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GNA11—melanoma	4.1e-05	8.62e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	4.09e-05	8.61e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGF—melanoma	4.09e-05	8.6e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—HRAS—melanoma	4.09e-05	8.59e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	4.06e-05	8.53e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—FASN—melanoma	4.05e-05	8.51e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1B—melanoma	4.02e-05	8.45e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—FASN—melanoma	4.01e-05	8.44e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—CYP1B1—melanoma	4.01e-05	8.43e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—SLC5A5—melanoma	3.98e-05	8.37e-05	CbGpPWpGaD
Tapentadol—OPRD1—GPCR downstream signaling—AKT1—melanoma	3.97e-05	8.35e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK3—melanoma	3.96e-05	8.34e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—SLC5A5—melanoma	3.95e-05	8.3e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CASP3—melanoma	3.94e-05	8.28e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL2—melanoma	3.93e-05	8.26e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—IL6—melanoma	3.91e-05	8.22e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—BRAF—melanoma	3.89e-05	8.18e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CB—melanoma	3.88e-05	8.16e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—PIK3CA—melanoma	3.87e-05	8.14e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MDM2—melanoma	3.86e-05	8.11e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CD44—melanoma	3.85e-05	8.09e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—GNAQ—melanoma	3.85e-05	8.09e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTGS2—melanoma	3.84e-05	8.08e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CCND1—melanoma	3.83e-05	8.06e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—GNAQ—melanoma	3.81e-05	8.02e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CD44—melanoma	3.81e-05	8.02e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—ERBB2—melanoma	3.8e-05	8e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CTNNB1—melanoma	3.79e-05	7.98e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IGF1—melanoma	3.79e-05	7.97e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—MAPK1—melanoma	3.77e-05	7.93e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—EGFR—melanoma	3.77e-05	7.93e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CB—melanoma	3.75e-05	7.89e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	3.73e-05	7.85e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MMP9—melanoma	3.72e-05	7.82e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—CDKN1A—melanoma	3.71e-05	7.79e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—melanoma	3.7e-05	7.78e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PTEN—melanoma	3.7e-05	7.78e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—CYP1B1—melanoma	3.69e-05	7.75e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NFKB1—melanoma	3.68e-05	7.74e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAP2K1—melanoma	3.66e-05	7.7e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—CYP1B1—melanoma	3.65e-05	7.68e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CD—melanoma	3.64e-05	7.65e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling by GPCR—AKT1—melanoma	3.61e-05	7.59e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CXCL8—melanoma	3.61e-05	7.58e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—PIK3CA—melanoma	3.6e-05	7.58e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—HRAS—melanoma	3.58e-05	7.53e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—KRAS—melanoma	3.56e-05	7.49e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.54e-05	7.44e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1B—melanoma	3.52e-05	7.41e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—FGF2—melanoma	3.48e-05	7.33e-05	CbGpPWpGaD
Tapentadol—OPRK1—GPCR downstream signaling—AKT1—melanoma	3.48e-05	7.33e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CASP3—melanoma	3.45e-05	7.26e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL2—melanoma	3.45e-05	7.25e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—IL6—melanoma	3.43e-05	7.21e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CCND1—melanoma	3.36e-05	7.06e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PTEN—melanoma	3.35e-05	7.05e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—VEGFA—melanoma	3.34e-05	7.02e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CTNNB1—melanoma	3.33e-05	7e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—STAT3—melanoma	3.31e-05	6.95e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ABCB1—melanoma	3.3e-05	6.94e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—NRAS—melanoma	3.3e-05	6.94e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—PIK3CA—melanoma	3.27e-05	6.88e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MMP9—melanoma	3.26e-05	6.86e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MDM2—melanoma	3.26e-05	6.85e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—CDKN1A—melanoma	3.25e-05	6.83e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PTEN—melanoma	3.24e-05	6.82e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NFKB1—melanoma	3.23e-05	6.79e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	3.23e-05	6.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—ERBB2—melanoma	3.21e-05	6.76e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CB—melanoma	3.17e-05	6.67e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling by GPCR—AKT1—melanoma	3.16e-05	6.65e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK3—melanoma	3.16e-05	6.64e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MYC—melanoma	3.07e-05	6.46e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CXCL8—melanoma	3.05e-05	6.41e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PRKCA—melanoma	3.04e-05	6.39e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ABCB1—melanoma	3.04e-05	6.38e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—HRAS—melanoma	3.03e-05	6.37e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ERCC2—melanoma	3.01e-05	6.33e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ABCB1—melanoma	3.01e-05	6.33e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—MAPK1—melanoma	3.01e-05	6.32e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—EGFR—melanoma	3.01e-05	6.32e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1B—melanoma	2.98e-05	6.26e-05	CbGpPWpGaD
Tapentadol—OPRM1—GPCR downstream signaling—AKT1—melanoma	2.94e-05	6.19e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—VEGFA—melanoma	2.93e-05	6.16e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CASP3—melanoma	2.92e-05	6.13e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL2—melanoma	2.91e-05	6.12e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—PIK3CA—melanoma	2.91e-05	6.12e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—STAT3—melanoma	2.9e-05	6.1e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—IL6—melanoma	2.9e-05	6.09e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—NRAS—melanoma	2.89e-05	6.08e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—KRAS—melanoma	2.84e-05	5.97e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CCND1—melanoma	2.84e-05	5.97e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CTNNB1—melanoma	2.81e-05	5.91e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PRKCA—melanoma	2.79e-05	5.87e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ERCC2—melanoma	2.77e-05	5.83e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK3—melanoma	2.77e-05	5.83e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PRKCA—melanoma	2.77e-05	5.82e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MMP9—melanoma	2.76e-05	5.8e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ERCC2—melanoma	2.75e-05	5.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—CDKN1A—melanoma	2.75e-05	5.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PTEN—melanoma	2.74e-05	5.76e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NFKB1—melanoma	2.73e-05	5.74e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MYC—melanoma	2.69e-05	5.67e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling by GPCR—AKT1—melanoma	2.67e-05	5.62e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—MAPK1—melanoma	2.64e-05	5.54e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—EGFR—melanoma	2.64e-05	5.54e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—PIK3CA—melanoma	2.61e-05	5.49e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—TP53—melanoma	2.52e-05	5.31e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.5e-05	5.25e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—KRAS—melanoma	2.49e-05	5.24e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—VEGFA—melanoma	2.48e-05	5.21e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—STAT3—melanoma	2.45e-05	5.15e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—NRAS—melanoma	2.45e-05	5.14e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—HRAS—melanoma	2.41e-05	5.08e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CG—melanoma	2.38e-05	5e-05	CbGpPWpGaD
Tapentadol—UGT2B7—Metabolism—AKT1—melanoma	2.38e-05	5e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—PIK3CA—melanoma	2.36e-05	4.97e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK3—melanoma	2.34e-05	4.92e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—IL6—melanoma	2.31e-05	4.86e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PPARG—melanoma	2.3e-05	4.83e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—PIK3CA—melanoma	2.29e-05	4.81e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MYC—melanoma	2.28e-05	4.79e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	2.28e-05	4.78e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—MAPK1—melanoma	2.23e-05	4.69e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—EGFR—melanoma	2.23e-05	4.68e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—TP53—melanoma	2.21e-05	4.65e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CG—melanoma	2.19e-05	4.6e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CG—melanoma	2.17e-05	4.56e-05	CbGpPWpGaD
Tapentadol—OPRD1—Signaling Pathways—AKT1—melanoma	2.13e-05	4.48e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—HRAS—melanoma	2.12e-05	4.45e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PPARG—melanoma	2.11e-05	4.44e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—KRAS—melanoma	2.1e-05	4.43e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PPARG—melanoma	2.09e-05	4.4e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CD—melanoma	2.09e-05	4.4e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—ALB—melanoma	2.06e-05	4.34e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—IL6—melanoma	2.03e-05	4.26e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—PIK3CA—melanoma	1.93e-05	4.07e-05	CbGpPWpGaD
Tapentadol—UGT1A9—Metabolism—AKT1—melanoma	1.93e-05	4.06e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CD—melanoma	1.92e-05	4.05e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CD—melanoma	1.91e-05	4.01e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—ALB—melanoma	1.9e-05	3.99e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—ALB—melanoma	1.88e-05	3.96e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—TP53—melanoma	1.87e-05	3.93e-05	CbGpPWpGaD
Tapentadol—OPRK1—Signaling Pathways—AKT1—melanoma	1.87e-05	3.93e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CB—melanoma	1.82e-05	3.83e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTGS2—melanoma	1.81e-05	3.8e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—HRAS—melanoma	1.79e-05	3.76e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—IL6—melanoma	1.71e-05	3.6e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CB—melanoma	1.68e-05	3.53e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CB—melanoma	1.66e-05	3.5e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTGS2—melanoma	1.66e-05	3.49e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTGS2—melanoma	1.65e-05	3.46e-05	CbGpPWpGaD
Tapentadol—OPRM1—Signaling Pathways—AKT1—melanoma	1.58e-05	3.32e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PTEN—melanoma	1.58e-05	3.31e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PTEN—melanoma	1.45e-05	3.05e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PTEN—melanoma	1.44e-05	3.02e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—PIK3CA—melanoma	1.11e-05	2.34e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—PIK3CA—melanoma	1.02e-05	2.15e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—PIK3CA—melanoma	1.01e-05	2.13e-05	CbGpPWpGaD
Tapentadol—CYP2C19—Metabolism—AKT1—melanoma	9.08e-06	1.91e-05	CbGpPWpGaD
Tapentadol—CYP2D6—Metabolism—AKT1—melanoma	8.35e-06	1.76e-05	CbGpPWpGaD
Tapentadol—CYP2C9—Metabolism—AKT1—melanoma	8.28e-06	1.74e-05	CbGpPWpGaD
